Application of cost-effectiveness analysis to post-menopausal estrogen therapy.
D000368:Aged; D000375:Aging / Q000187:drug effects; D001943:Breast Neoplasms / Q000139:chemically induced; D002979:Climacteric; D003327:Coronary Disease / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D004644:Emotions / Q000187:drug effects; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008722:Methods; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control; D011788:Quality of Life; D013997:Time Factors; D014594:Uterine Neoplasms / Q000139:chemically induced
D004967:Estrogens; D004966:Estrogens, Conjugated (USP)